Novo Nordisk

Page 4 of 8

Half of Denmark’s GDP growth in 2024 will be thanks to Novo Nordisk, analysts predict
Tech

Half of Denmark’s GDP growth in 2024 will be thanks to Novo Nordisk, analysts predict

By Sanne Wass and Bloomberg
September 3, 2024
A photo of the packet for anti-obesity drug Wegovy.
Health

Wegovy reduced Covid deaths in obese patients, study finds

By Madison Muller and Bloomberg
August 30, 2024
A person sifts through a rack of clothing.
Retail

Secondhand luxury fashion thrives as Ozempic users purge their closets

By
August 29, 2024
Novo Nordisk’s weight-loss drugs and Bavarian Nordic’s mpox vaccine help fatten up the Danish economy
Finance

Novo Nordisk’s weight-loss drugs and Bavarian Nordic’s mpox vaccine help fatten up the Danish economy

By Sanne Wass and Bloomberg
August 20, 2024
Norway’s $1.7 trillion wealth fund made billions from tech in 2024—now it’s slashing its stake in Meta, Novo Nordisk and ASML
Finance

Norway’s $1.7 trillion wealth fund made billions from tech in 2024—now it’s slashing its stake in Meta, Novo Nordisk and ASML

By Kari Lundgren and Bloomberg
August 14, 2024
Here’s the real reason Ozempic-like weight-loss drugs are so popular
Commentary

Here’s the real reason Ozempic-like weight-loss drugs are so popular

By
August 12, 2024
An Ozempic (semaglutide) injection pen is seen on a kitchen table.
Health

How Denmark got homegrown giant Novo Nordisk to lower Ozempic prices

By Arthur Allen and KFF Health News
August 7, 2024
Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk, speaks during a Bloomberg Television interview in New York, US, on Wednesday, Aug. 10, 2022. Two more factories will begin producing Novo Nordisk A/S's obesity medication Wegovy next year after manufacturing issues and high demand left the drug in short supply, Jorgensen said. Photographer: Christopher Goodney/Bloomberg via Getty Images
Retail

Europe’s most valuable company Novo Nordisk reports an uptick in profits as demand for weight-loss drugs continues to grow

By
August 7, 2024
In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
Newsletters

In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs

By
August 5, 2024
Angela Fitch. cofounder and chief medical officer of knownwell.
Commentary

I’m an obesity medicine doctor and I’ve been on weight-loss drugs like Ozempic for a decade. Here’s why I think they aren’t a fad

By
July 30, 2024
Thomas Schinecker, chief executive officer of Roche
Finance

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

By
July 29, 2024
Thomas Schinecker, CEO of Roche Holding.
Retail

An obesity pill study tested on just 25 patients led to a stunning $16.8 billion increase in Swiss drugmaker Roche’s market value

By Naomi Kresge, Lisa Pham and Bloomberg
July 23, 2024
A bathroom scale is surrounded by colorful pills.
Health

Pharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots

By Damian Garde and Bloomberg
July 11, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
Features

Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree

By Jessica Mathews and Alena Botros
July 9, 2024
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
Health

Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs

By
June 28, 2024

Most Popular